Drug Information
Drug (ID: DG01531) and It's Reported Resistant Information
Name |
Cobimetinib
|
||||
---|---|---|---|---|---|
Synonyms |
Cobimetinib; 934660-93-2; GDC-0973; XL518; Cotellic; Xl-518; GDC 0973; RG7420; XL 518; RG 7420; UNII-ER29L26N1X; ER29L26N1X; C21H21F3IN3O2; CHEMBL2146883; XL518 (GDC-0973); Cobimetinib (GDC-0973, RG7420); (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; EUI; Cobimetinib Butyrate; Cobimetinib [USAN:INN]; cometinib; Cobimetinib (USAN/INN); SCHEMBL189565; GTPL7626; QCR-87; XL518;RG7420;Cobimetinib; CHEBI:90851; DTXSID60239435; EX-A673; GDC0973; GDC0973; XL518; Cobimetinib; 3556AH; BDBM50391802; MFCD22124461; NSC768068; NSC781257; NSC800075; s8041; ZINC60325170; BCP9000716; CCG-264727; CS-0521; DB05239; NSC-768068; NSC-781257; NSC-800075; VS-0129; NCGC00346455-03; NCGC00346455-05; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; HY-13064; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)-; RO-5514041; D10405; J-525162; Q15708292; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((S)-piperidin-2-yl)cyclobutyl)methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
[2]
|
||||
Target | cAMP-dependent chloride channel (CFTR) | CFTR_HUMAN | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
4
|
||||
IsoSMILES |
C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
|
||||
InChI |
InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1
|
||||
InChIKey |
BSMCAPRUBJMWDF-KRWDZBQOSA-N
|
||||
PubChem CID | |||||
ChEBI ID | |||||
TTD Drug ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.V211D (c.632T>A) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | NIH-3T3 cells | Embryo | Mus musculus (Mouse) | CVCL_0594 |
Phoenix AMPHO cells | Fetal kidney | Homo sapiens (Human) | CVCL_H716 | |
In Vivo Model | NOD scid gamma xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Single cell sequencing assay |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Complex-indel | p.N486_T491delinsK (c.1458_1472del15) |
||
Sensitive Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay | |||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [3] | |||
Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
||
Sensitive Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Mechanism Description | The missense mutation p.V600E (c.1799T>A) in gene BRAF cause the sensitivity of Cobimetinib by unusual activation of pro-survival pathway |
Melanoma [ICD-11: 2C30]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [4] | |||
Molecule Alteration | Missense mutation | p.L597S (c.1789_1790delCTinsTC) |
||
Sensitive Disease | Melanoma [ICD-11: 2C30.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | MAPK signaling pathway | Inhibition | hsa04010 | |
In Vitro Model | Skin sample | N.A. | ||
In Vivo Model | Mouse PDX model | Mus musculus | ||
Experiment for Drug Resistance |
Crystal violet staining assay |
Lymphatic system cancer [ICD-11: 2E81]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [1] | |||
Molecule Alteration | Missense mutation | p.P124L (c.371C>T) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [5] | |||
Molecule Alteration | Missense mutation | p.Q56P (c.167A>C) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [1] | |||
Molecule Alteration | IF-deletion | p.P105_I107delPAI (c.314_322delCCGCAATCC) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [1] | |||
Molecule Alteration | Missense mutation | p.P124Q (c.371C>A) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Complex-indel | p.N486_T491delinsK (c.1458_1472del15) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay | |||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
||
Sensitive Disease | Lymphatic system cancer [ICD-11: 2E81.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
Experiment for Molecule Alteration |
Whole exome sequencing; Targeted Exon Sequencing | |||
Experiment for Drug Resistance |
CellTiter-Glo assay; IC50 assay |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.